CRTH.F Stock Overview
An investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
CARsgen Therapeutics Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.76 |
| 52 Week High | HK$1.67 |
| 52 Week Low | HK$0.75 |
| Beta | 0.43 |
| 1 Month Change | 0% |
| 3 Month Change | 1.81% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -62.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| CRTH.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -1.7% | -1.1% |
| 1Y | n/a | -5.0% | 22.4% |
Return vs Industry: Insufficient data to determine how CRTH.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how CRTH.F performed against the US Market.
Price Volatility
| CRTH.F volatility | |
|---|---|
| CRTH.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CRTH.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CRTH.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 477 | Zonghai Li | www.carsgen.com |
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is developing autologous CAR-T product candidates, including CT053, which targets B-cell maturation antigen that is in pivotal Phase II/III trial for the treatment of relapsed/refractory multiple myeloma; CT041, which targets Claudin 18.2, is in Phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in Phase I clinical trial for gastric or pancreatic cancer; CT011, which is in Phase I clinical trial for patients with Glypican-3 positive IIIa hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial which targets G protein-coupled receptor class C group 5 member D for the treatment of R/R MM and relapsed/refractory primary plasma cell leukemia (R/R pPCL). It is also developing CT0180 and CT0181, which targets Glypican-3 that is in Phase I clinical trial for the treatment of hepatocellular carcinoma.
CARsgen Therapeutics Holdings Limited Fundamentals Summary
| CRTH.F fundamental statistics | |
|---|---|
| Market cap | US$197.90m |
| Earnings (TTM) | -US$97.70m |
| Revenue (TTM) | US$891.43k |
216.2x
P/S Ratio-2.0x
P/E RatioIs CRTH.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRTH.F income statement (TTM) | |
|---|---|
| Revenue | CN¥6.34m |
| Cost of Revenue | CN¥4.72m |
| Gross Profit | CN¥1.62m |
| Other Expenses | CN¥696.50m |
| Earnings | -CN¥694.88m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.22 |
| Gross Margin | 25.50% |
| Net Profit Margin | -10,960.25% |
| Debt/Equity Ratio | 8.6% |
How did CRTH.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/11 14:25 |
| End of Day Share Price | 2024/06/14 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CARsgen Therapeutics Holdings Limited is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xiao Wei Lin | Everbright Securities Co. Ltd. |
| Ziyi Chen | Goldman Sachs |